Tonix Pharmaceuticals receives Fast Track designation from FDA for TNX-102 SL
Tonix Pharmaceuticals announced the FDA has granted Fast Track designation to its investigational new drug, TNX-102 SL, for treatment of agitation in Alzheimer’s disease. It is currently in a Phase 3 study for military-related PTSD, with an interim analysis expected in the third quarter of 2018. July 16, 2018